How Do Pharmaceutical Companies View TRIPS in Relation to Cancer?
Pharmaceutical companies often advocate for strong IP rights, arguing that patents are essential for recouping research and development costs associated with new cancer drugs. They claim that without the protection that TRIPS offers, the incentive to innovate would diminish, potentially slowing down the discovery of new cancer treatments. However, critics argue that excessive protection can hinder access to essential medicines and that companies should strike a balance between innovation and affordability.
